These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 25083560)
1. Mass spectrometric analysis of the phosphorylation levels of the SWI/SNF chromatin remodeling/tumor suppressor proteins ARID1A and Brg1 in ovarian clear cell adenocarcinoma cell lines. Kimura A; Arakawa N; Hirano H J Proteome Res; 2014 Nov; 13(11):4959-69. PubMed ID: 25083560 [TBL] [Abstract][Full Text] [Related]
2. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma. Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887 [TBL] [Abstract][Full Text] [Related]
3. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Guan B; Wang TL; Shih IeM Cancer Res; 2011 Nov; 71(21):6718-27. PubMed ID: 21900401 [TBL] [Abstract][Full Text] [Related]
4. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level. Goldman AR; Bitler BG; Schug Z; Conejo-Garcia JR; Zhang R; Speicher DW Mol Cell Proteomics; 2016 Nov; 15(11):3348-3360. PubMed ID: 27654507 [TBL] [Abstract][Full Text] [Related]
5. HIC1 interacts with a specific subunit of SWI/SNF complexes, ARID1A/BAF250A. Van Rechem C; Boulay G; Leprince D Biochem Biophys Res Commun; 2009 Aug; 385(4):586-90. PubMed ID: 19486893 [TBL] [Abstract][Full Text] [Related]
6. SWI/SNF chromatin remodeling complex is critical for the expression of microphthalmia-associated transcription factor in melanoma cells. Vachtenheim J; Ondrusová L; Borovanský J Biochem Biophys Res Commun; 2010 Feb; 392(3):454-9. PubMed ID: 20083088 [TBL] [Abstract][Full Text] [Related]
7. Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. Morita A; Miyagi E; Yasumitsu H; Kawasaki H; Hirano H; Hirahara F Proteomics; 2006 Nov; 6(21):5880-90. PubMed ID: 17022098 [TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Sun A; Tawfik O; Gayed B; Thrasher JB; Hoestje S; Li C; Li B Prostate; 2007 Feb; 67(2):203-13. PubMed ID: 17075831 [TBL] [Abstract][Full Text] [Related]
9. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma. Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703 [TBL] [Abstract][Full Text] [Related]
10. ARID1A deficiency weakens BRG1-RAD21 interaction that jeopardizes chromatin compactness and drives liver cancer cell metastasis. Shang XY; Shi Y; He DD; Wang L; Luo Q; Deng CH; Qu YL; Wang N; Han ZG Cell Death Dis; 2021 Oct; 12(11):990. PubMed ID: 34689165 [TBL] [Abstract][Full Text] [Related]
11. ARID1A mutations in endometriosis-associated ovarian carcinomas. Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669 [TBL] [Abstract][Full Text] [Related]
12. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Reisman DN; Strobeck MW; Betz BL; Sciariotta J; Funkhouser W; Murchardt C; Yaniv M; Sherman LS; Knudsen ES; Weissman BE Oncogene; 2002 Feb; 21(8):1196-207. PubMed ID: 11850839 [TBL] [Abstract][Full Text] [Related]
13. The BRG1 ATPase of chromatin remodeling complexes is involved in modulation of mesenchymal stem cell senescence through RB-P53 pathways. Alessio N; Squillaro T; Cipollaro M; Bagella L; Giordano A; Galderisi U Oncogene; 2010 Oct; 29(40):5452-63. PubMed ID: 20697355 [TBL] [Abstract][Full Text] [Related]
14. The BRG1 chromatin remodeler protects against ovarian cysts, uterine tumors, and mammary tumors in a lineage-specific manner. Serber DW; Rogala A; Makarem M; Rosson GB; Simin K; Godfrey V; Van Dyke T; Eaves CJ; Bultman SJ PLoS One; 2012; 7(2):e31346. PubMed ID: 22363625 [TBL] [Abstract][Full Text] [Related]
15. The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II. Trizzino M; Barbieri E; Petracovici A; Wu S; Welsh SA; Owens TA; Licciulli S; Zhang R; Gardini A Cell Rep; 2018 Jun; 23(13):3933-3945. PubMed ID: 29949775 [TBL] [Abstract][Full Text] [Related]
16. SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. Banine F; Bartlett C; Gunawardena R; Muchardt C; Yaniv M; Knudsen ES; Weissman BE; Sherman LS Cancer Res; 2005 May; 65(9):3542-7. PubMed ID: 15867346 [TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of Ser1452 on BRG1 inhibits the function of the SWI/SNF complex in chromatin activation. Kimura A; Arakawa N; Kagawa H; Kimura Y; Hirano H J Proteomics; 2021 Sep; 247():104319. PubMed ID: 34237461 [TBL] [Abstract][Full Text] [Related]
18. Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription. Yan HB; Wang XF; Zhang Q; Tang ZQ; Jiang YH; Fan HZ; Sun YH; Yang PY; Liu F Carcinogenesis; 2014 Apr; 35(4):867-76. PubMed ID: 24293408 [TBL] [Abstract][Full Text] [Related]
19. A switch from hBrm to Brg1 at IFNγ-activated sequences mediates the activation of human genes. Zhang Y; Cheng MB; Zhang YJ; Zhong X; Dai H; Yan L; Wu NH; Zhang Y; Shen YF Cell Res; 2010 Dec; 20(12):1345-60. PubMed ID: 21079652 [TBL] [Abstract][Full Text] [Related]
20. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Glaros S; Cirrincione GM; Muchardt C; Kleer CG; Michael CW; Reisman D Oncogene; 2007 Oct; 26(49):7058-66. PubMed ID: 17546055 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]